ArticlePloS one2011
Gene-expression signatures can distinguish gastric cancer grades and stages.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis Reveals the Prognostic Relevance of Nuclear and Membrane-Associated Bile Acid Receptors in Gastric Cancer.Clinical and translational gastroenterology · 2021Pooled it
- Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines.Scientific reports · 2026Article
- Ephrin-A4 ligand promotes gastric cancer cell epithelial-mesenchymal transition via the PI3K/AKT signaling pathway.Discover oncology · 2026Article
- Bioinspired pH-sensitive liposomes for quercetin delivery to synergize with 5- FU in gastric cancer therapy.International journal of pharmaceutics: X · 2025Article
- Long Non-Coding RNA DUXAP10 Promotes Tumorigenesis and Metastasis in Anaplastic Thyroid Cancer.Cancers · 2025Article
- Low muscle mass in lung cancer is associated with an inflammatory and immunosuppressive tumor microenvironment.Journal of translational medicine · 2023Article
- The Comprehensive Analysis of N6-Methyadenosine Writer METTL3 and METTL14 in Gastric Cancer.Journal of oncology · 2023Article
- FHOD1 is upregulated in gastric cancer and promotes the proliferation and invasion of gastric cancer cells.Oncology letters · 2021Article
- AGXT2L1 is downregulated in carcinomas of the digestive system.Oncology letters · 2020Article
- Enhancing reproducibility of gene expression analysis with known protein functional relationships: The concept of well-associated protein.PLoS computational biology · 2020Article
- Discovery of Prognostic Signature Genes for Overall Survival Prediction in Gastric Cancer.Computational and mathematical methods in medicine · 2020Article
- In silico markers: an evolutionary and statistical approach to select informative genes of human breast cancer subtypes.Genes & genomics · 2019Article
- High Expression ofJournal of clinical medicine · 2019Article
- Five-long non-coding RNA risk score system for the effective prediction of gastric cancer patient survival.Oncology letters · 2019Article
- Protein interaction disruption in cancer.BMC cancer · 2019Article
- The opposite role of alternatively spliced isoforms of LINC00477 in gastric cancer.Cancer management and research · 2019Article
- Replication-dependent histone isoforms: a new source of complexity in chromatin structure and function.Nucleic acids research · 2018Review
- New therapeutic options opened by the molecular classification of gastric cancer.World journal of gastroenterology · 2018Review
- Curated compendium of human transcriptional biomarker data.Scientific data · 2018Article
- Identification of Potential Key Genes Associated With the Pathogenesis and Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis.Frontiers in genetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Microarray gene-expression data of 54 paired gastric cancer and adjacent noncancerous gastric tissues were analyzed, with the aim to establish gene signatures for cancer grades (well-, moderately-, poorly- or un-differentiated) and stages (I, II, III and IV), which have been determined by pathologists. Our statistical analysis led to the identification of a number of gene combinations whose expression patterns serve well as signatures of different grades and different stages of gastric cancer. A 19-gene signature was found to have discerning power between high- and low-grade gastric cancers in general, with overall classification accuracy at 79.6%. An expanded 198-gene panel allows the stratification of cancers into four grades and control, giving rise to an overall classification agreement of 74.2% between each grade designated by the pathologists and our prediction. Two signatures for cancer staging, consisting of 10 genes and 9 genes, respectively, provide high classification accuracies at 90.0% and 84.0%, among early-, advanced-stage cancer and control. Functional and pathway analyses on these signature genes reveal the significant relevance of the derived signatures to cancer grades and progression. To the best of our knowledge, this represents the first study on identification of genes whose expression patterns can serve as markers for cancer grades and stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.